Nature, Год журнала: 2023, Номер unknown
Опубликована: Окт. 18, 2023
Язык: Английский
Nature, Год журнала: 2023, Номер 623(7985), С. 157 - 166
Опубликована: Окт. 18, 2023
Abstract Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM) 1,2 . Here we report results a first-in-human phase I trial in 41 patients with rGBM who were injected CAN-3110—an oncolytic herpes virus (oHSV) 3 In contrast to other clinical oHSVs, CAN-3110 retains viral neurovirulence ICP34.5 gene transcribed by nestin promoter; is overexpressed GBM and invasive tumours, but not adult brain or healthy differentiated tissue 4 These modifications confer preferential replication. No dose-limiting toxicities encountered. Positive HSV1 serology was significantly associated both improved survival clearance tumours. Survival after treatment, particularly individuals seropositive for HSV1, (1) changes tumour/PBMC T cell counts clonal diversity, (2) peripheral expansion/contraction specific clonotypes; (3) transcriptomic signatures immune activation. provide human validation intralesional oHSV treatment enhances anticancer responses even immunosuppressive microenvironments, cognate virus. This provides biological rationale use this modality cancers are otherwise unresponsive immunotherapy (ClinicalTrials.gov: NCT03152318 ).
Язык: Английский
Процитировано
105
Current Treatment Options in Oncology, Год журнала: 2024, Номер 25(7), С. 952 - 991
Опубликована: Июнь 19, 2024
Язык: Английский
Процитировано
4
Nature Communications, Год журнала: 2025, Номер 16(1)
Опубликована: Янв. 14, 2025
Glioma is a highly fatal and heterogeneous brain tumor with few known risk factors. Our study examines genetically predicted variability in blood cell indices relation to glioma survival 3418 cases 8156 controls. We find that increased platelet lymphocyte ratio (PLR) confers an of (odds (OR) = 1.25, p 0.005), especially tumors isocitrate dehydrogenase (IDH) mutations (OR 1.38, 0.007) IDHmut 1p/19q intact (IDHmut-intact OR 1.53, 0.004) tumors. Genetically inferred counts lymphocytes 0.70, neutrophils (IDHmut 0.69, 0.019; IDHmut-intact 0.60, 0.009) show inverse associations risk, which may reflect enhanced immune-surveillance. Considering survival, we observe higher mortality patients (hazard (HR) 1.65, 95% CI: 1.24–2.20), (HR 1.49, 1.13–1.97), eosinophils 1.59, 1.18–2.14). Polygenic scores for traits are also differentially associated 17 immune microenvironment features subtype-specific manner, including signatures related interferon signaling, PD-1 expression, T-cell/Cytotoxic responses. findings highlight immune-mediated susceptibility mechanisms potential disease management implications. aggressive subtype Here, the authors utilise Mendelian Randomisation investigate correlation patients.
Язык: Английский
Процитировано
0
Опубликована: Март 19, 2025
胶质母细胞瘤是一种棘手的神经系统恶性肿瘤，由于其较高的侵袭性、异质性、代谢率，患者中位生存期通常只有12~15个月。在胶质瘤中，肿瘤相关巨噬细胞甚至占到30%~50%,先前研究表明，巨噬细胞极化为M1表型巨噬细胞 （经典激活巨噬细胞）和M2表型巨噬细胞 （替代激活巨噬细胞）。后者多具有促进肿瘤生长的作用。通过加入细胞因子改变肿瘤微环境，促进M2型肿瘤相关巨噬细胞向M1型巨噬细胞转化是当前治疗的一种策略。近年研究发现肿瘤细胞和微环境通过调控基因信号通路参与巨噬细胞向M2型极化的过程。处于不同的微环境下巨噬细胞的行为和物质代谢得以揭示，临床试验也取得许多进展，运用纳米技术作为药物载体来进入到传统手术无法切除的游离肿瘤细胞,基因编辑肿瘤细胞，采用光动力疗法传递药物，靶向治疗的基础上采用多种方法联合治疗，从而延长患者生存期。文章综述了M2巨噬细胞在胶质瘤中的代谢机制，并分析相关临床研究，为今后基础研究和临床治疗提供方向。
Процитировано
0
JNCI Journal of the National Cancer Institute, Год журнала: 2024, Номер unknown
Опубликована: Окт. 24, 2024
Previous epidemiologic studies have reported an association of serum immunoglobulin E (IgE) levels with reduced glioma risk, but the between IgE and prognosis has not been characterized. This study aimed to examine how sex, tumor subtype, class modulate risk survival.
Язык: Английский
Процитировано
3
npj Precision Oncology, Год журнала: 2024, Номер 8(1)
Опубликована: Сен. 29, 2024
Язык: Английский
Процитировано
1
medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown
Опубликована: Май 9, 2024
ABSTRACT Background Previous epidemiologic studies have reported an association of serum immunoglobulin E (IgE) levels with reduced glioma risk, but the between IgE and prognosis has not been characterized. This study aimed to examine how sex, tumor subtype, class modulate risk survival. Methods We conducted a case-control using participants from University California, San Francisco Adult Glioma Study (1997-2010). Serum for total, respiratory food allergy were measured in adults diagnosed (n=1319) cancer-free controls (n=1139) matched based on age, race ethnicity. Logistic regression was adjusted patient demographics assess risk. Multivariable Cox patient-specific tumor-specific factors compared survival elevated normal groups. All statistical tests 2-sided. Results Elevated total associated IDH-wildtype (RR=0.78, 95% CI: 0.71-0.86) IDH-mutant (RR=0.73, 0.63-0.85). In multivariable regression, positive improved (RR=0.79, 0.67-0.93). The reduction mortality significant females only (RR=0.75, 0.57-0.98) improvement median 6.9 months (P<.001). Conclusion glioma, more pronounced protective effect than males, which implications future IgE-based immunotherapies glioma.
Язык: Английский
Процитировано
0
Neuro-Oncology Advances, Год журнала: 2024, Номер 6(1)
Опубликована: Янв. 1, 2024
Abstract Background Variations in survival among patients with oligodendroglioma are unexplained by known prognostic factors. To assess the impact of peripheral immune profiles on prognosis, we applied immunomethylomics analyses—DNA methylation archived whole blood samples, to characterize cells. Methods We compared proportions cells from other glioma subtypes and controls. used recursive partitioning analysis (RPA) within oligodendrogliomas correlate survival. Results Patients (141) were median age at diagnosis 44 years; 57% male; 75% White; 60% prior chemotherapy; 25% dexamethasone sample collection. had more similar controls than subtypes, though notably lower B-cells. RPA delineated 2 groups based an interaction between B-naïve longer (median 24.2 years) ≤42 years higher versus worse 16.9 who or >42 (P = .00032). also CD4- CD8-naïve T-cells. Similar observed independent cohort surgery. Conclusions Peripheral suggested that younger experienced shorter Though our findings lack validation use a heterogenous patient population, they suggest may be for warrant further investigation.
Язык: Английский
Процитировано
0
Neuro-Oncology, Год журнала: 2023, Номер 26(2), С. 209 - 210
Опубликована: Ноя. 6, 2023
Journal Article Oncolytic immunoactivation associates with survival in a glioblastoma clinical trial Get access Alexander L Ling, Ling Harvey Cushing Neuro-oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar E Antonio Chiocca Corresponding Author: E. Chiocca, MD, PhD, MA 02115, ([email protected]) https://orcid.org/0000-0001-5183-1670 Neuro-Oncology, Volume 26, Issue 2, February 2024, Pages 209–210, https://doi.org/10.1093/neuonc/noad216 Published: 06 November 2023 history Corrected typeset: 24
Язык: Английский
Процитировано
1
Neuro-Oncology, Год журнала: 2023, Номер 25(10), С. 1910 - 1912
Опубликована: Авг. 18, 2023
Journal Article Inherited polymorphisms in the Human Leukocyte Antigen Region modify association between varicella-zoster virus antibody reactivity and glioma prognosis Get access Stephen S Francis, Francis Department of Neurological Surgery, University California San Francisco, California, USADepartment Epidemiology Biostatistics, USAWeill Institute for Neurosciences, USA Corresponding Author: S. MS, PhD, Weill 1450 3rd St, CA 94158USA ([email protected]). https://orcid.org/0000-0002-6488-6272 Search other works by this author on: Oxford Academic PubMed Google Scholar Geno Guerra, Guerra https://orcid.org/0000-0001-9870-9998 Helen M Hansen, Hansen George Wendt, Wendt Linda Kachuri, Kachuri Population Health, Stanford University, Stanford, USAStanford Cancer Institute, John K Wiencke, Wiencke Margaret Wrensch Neuro-Oncology, Volume 25, Issue 10, October 2023, Pages 1910–1912, https://doi.org/10.1093/neuonc/noad122 Published: 18 August 2023 history Corrected typeset:
Язык: Английский
Процитировано
0